Figure 2

Figure 2

MRI non-progressors at Month 4 and Month 12 in (A) synovitis score, (B) osteitis score and (C) erosion score. Treatment groups represent treatment received in the DB period. Data are presented for all patients who had MRIs available at the visits of interest (as-observed analysis); patients with MRI outside of Days 92–134 were excluded from the Day 113 (Month 4) analysis, and with MRI >4 weeks prior to or after Day 337 were excluded from the Month 12 MRI analysis. Non-progressors defined by mean change from baseline in MRI score <1 RAMRIS unit. Error bars represent 95% CI. Synovitis was assessed only in the wrist, whereas osteitis and erosion were assessed in the wrist and MCP joints. DB, double-blind; MCP, metacarpophalangeal; MTX, methotrexate; RAMRIS, rheumatoid arthritis MRI score.